Lexicon Pharmaceuticals Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Lexicon Pharmaceuticals saw a drop in short interest in January. As of January 29th, there was short interest totaling 5,360,000 shares, a drop of 52.9% from the January 14th total of 11,380,000 shares. Based on an average trading volume of 11,230,000 shares, the short-interest ratio is presently 0.5 days.
View Lexicon Pharmaceuticals' Short Interest.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals will be holding an earnings conference call on Wednesday, March 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.26. The biopharmaceutical company had revenue of $6.63 million for the quarter, compared to analysts' expectations of $119.16 million. Lexicon Pharmaceuticals had a negative net margin of 320.44% and a negative trailing twelve-month return on equity of 164.96%.
View Lexicon Pharmaceuticals' earnings history.

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LXRX stock has increased by 198.7% and is now trading at $6.78.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 12-month target prices for Lexicon Pharmaceuticals' shares. Their forecasts range from $6.00 to $13.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $9.40 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of LXRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (58.74%), BlackRock Inc. (2.42%), Morgan Stanley (1.72%), Pinnacle Associates Ltd. (1.53%), Renaissance Technologies LLC (0.82%) and Charles Schwab Investment Management Inc. (0.28%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., Price T Rowe Associates Inc. MD, Squarepoint Ops LLC, and Strs Ohio.
View insider buying and selling activity for Lexicon Pharmaceuticals or view top insider-selling stocks.

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Pinnacle Associates Ltd., Morgan Stanley, Vontobel Holding Ltd., Salem Investment Counselors Inc., Charles Schwab Investment Management Inc., Principal Financial Group Inc., and Quantitative Systematic Strategies LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals or or view top insider-buying stocks.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LXRX stock can currently be purchased for approximately $6.78.

Lexicon Pharmaceuticals has a market capitalization of $821.63 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis.

Lexicon Pharmaceuticals employs 184 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000 or via email at [email protected]